News and Trends 24 Oct 2017 British Scientists Prove that it Takes Very Few Mutations to Cause Cancer Researchers in the UK have analyzed over 7,500 tumors and estimate that a very low number of mutations is needed for cancer to develop. Researchers coming out of the prestigious Sanger Institute in Cambridge, UK has estimated that as few as 1 to 10 mutations are required to cause cancer. The study, published in Cell, was […] October 24, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2017 French Biotech‘s Bacterial Product is Ready to Enter the Anti-Aging Skincare Market Montpellier-based Deinove has developed a bacterial anti-aging skincare product, which has shown its safety and healing capacity in studies so far. Deinove specializes in high-value compounds from rare bacteria, in particular, the Deinococcus genus. It has announced that it will launch its first cosmetic product into the anti-aging skincare market in 2018, which is based on a […] October 24, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 24 Oct 2017 Where to Find the Money to Get Your Biotech Startup Up with the Big Boys What do you need to kickstart your own biotech company? A great idea, of course. Industry knowledge, a plus. Money… This could be tricky. Breaking into the biotech industry is one of the most expensive decisions that you can make. First, you need ground-breaking science that has what it takes to change its respective field, […] October 24, 2017 - 8 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Oct 2017 FDA Grants Belgian Crohn’s Disease Candidate Orphan Designation TiGenix’s candidate for a nasty Crohn’s disease complication received orphan drug designation after agreeing on a global Phase III trial. TiGenix exploits the anti-inflammatory properties of donor-derived stem cells to treat diseases. One of its candidates, Cx601, is targeted at a complication of Crohn’s disease – a nasty inflammatory condition affecting the intestine. Cx601 met efficacy and safety […] October 23, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Oct 2017 Transgene‘s Hepatitis B Vaccine Does the Business at Phase I The French biotech‘s hepatitis B vaccine has demonstrated good efficacy and safety, suggesting it could provide effective protection from the virus. Biotech veteran, Transgene, specializes in viral-based immunotherapies for cancers and infectious diseases. One of its targets, hepatitis B, is a potentially fatal liver infection caused by the hepatitis B virus (HBV). Today, it has […] October 23, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Oct 2017 Swiss Biotech Rakes in $200M to Accelerate Antibody-based Cancer Treatments ADC Therapeutics has received massive private funding to progress two of its lead candidates for cancer through clinical trials. ADC Therapeutics, based in Lausanne, Switzerland, specializes in developing antibody-drug conjugates (ADCs) for the treatment of cancer. The technology uses the specificity of antibodies to deliver a therapeutic agent to target cells only. The biotech has […] October 23, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2017 Leading Pharma-Academic Partnership Unravels the Mystery of a Major Cancer Gene The PTEN gene controls cell growth and behavior, with its loss implicated in cancer. AstraZeneca and Babraham have collaborated to improve our understanding of how this happens. The Babraham Institute, Cambridge, UK and AstraZeneca have unveiled research that helps us to better understand a key cancer gene, PTEN – reportedly the second most altered gene in cancers. […] October 20, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2017 Personalized Breast Cancer Treatment Coming Soon with Help from Spanish Biotech Inbiomotion has published the results of a Phase III study looking at its MAFTest to personalized approaches to the disease. Inbiomotion, based in Barcelona’s biotech hub, works on a highly selective biomarker for breast cancer. A Phase III study demonstrated that breast cancer patients that would benefit from zoledronic acid therapy can be selected, helping clinicians offer […] October 19, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2017 Austrian Researchers Identify Target for Treatment of Multiple Sclerosis Multiple sclerosis is the most common disease of the CNS in young adults. Researchers may have stumbled across a new approach for its treatment. Researchers at the Medical University of Vienna have identified a target for the treatment of multiple sclerosis (MS). The research, published in the Journal of Autoimmunity, found that histone deacetylases (HDACs) play […] October 19, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2017 German Researchers Set the Immune System Free to Fight Against Cancer There could be a way to stop cancers escaping from the immune system, and researchers hope to use this for more effective cancer treatments. Researchers at Universität Bonn have found a way to “release the brakes” in the immune system that helps cancers to survive. Cancers benefit from this by pretending to be regular cells, […] October 18, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2017 Biotech Crosses the Channel to Raise €9.7M for its Diagnostics Tools Novacyt will use the money raised on the AIM market, London, to expand its manufacturing capacity and continue research looking into new techniques. Novacyt specializes in diagnostic tools for a number of indications, including cancer and infectious diseases. Today, it has announced that it has raised €9.7M by placing stocks on the London-based Alternative Investment Market (AIM). […] October 18, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2017 Swedish Human Cell Atlas gets the Support of Chan & Zuckerberg The Human Cell Atlas will map all of the cells in the body, and the Chan Zuckerberg Initiative has given a grant to Swedish researchers to join the project. Mark Zuckerberg and his wife, Priscilla Chan, founded the Chan Zuckerberg Initiative to provide resources for projects, including biomedical research. The Initiative supports the Human Cell Atlas, an exciting […] October 17, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email